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Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), 
neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the 
pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is 
considered to be a cause of VKH  disease. The complex immunological response to interferon and ribavirin may induce or exacerbate 
the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic 
hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic 
hepatitis C. (Korean J Hepatol 2011;17:61-65)
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INTRODUCTION
Interferon combined with ribavirin is commonly used in 
treating chronic hepatitis C. Interferon sometimes results in 
common side effects such as flu-like symptoms, fatigue, 
myalgia, headache, and in rare but fatal ones such as depression, 
suppressed bone marrow, interstitial pneumonia, diabetes, or 
autoimmune diseases.
1 Vogt-Koyanagi-Harada (VKH) disease 
is a multi-systemic granulomatous inflammatory disease 
with ophthalmic involvement (uveitis and retinal detachment), 
ear and meningeal involvement (headache, tinnitus, and 
encephalomeningitis), and skin and hair change (vitiligo, 
alopecia, and poliosis). It is a very rare complication associated 
with the interferon treatments.
2 The mechanism of VKH 
disease has not been known yet, but it is presumed that 
interferon brings alterations to the immunological responses 
to melanocytes.
3 We report a case of VKH disease which 
occurred during pegylated interferon and ribavirin therapy 
for chronic hepatitis C.
CASE REPORT
A 58-year-old woman visited our hospital for evaluation 
of chronic hepatitis C. The patient was diagnosed as chronic 
hepatitis C 10 years ago, but had not received any treatment. 
She had been taking amlodipine 5 mg for hypertension for 8 
years. She had no history of alcohol consumption, smoking, 
or injection drug use. Dermatological, pulmonary, cardiac 
and neurological examinations were normal. On her first 
visit to our hospital, the liver function test and the complete 
blood cell count were normal, and the serologic tests for 
hepatitis A and B and HIV were negative. She was infected 
with hepatitis C virus (HCV) genotype 1b, and HCV RNA 
level was 3.8×10
6 copies/mL. There were no specific findings 
except for the hepatic cyst from abdominal CT scan. Liver 
biopsy was recommended to evaluate liver inflammation and 62  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
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Figure 1. The patient's face before treatment (A). The 5-cm vitiligo on the forehead appears after 9 months of pegylated interferon-α2b 
and ribavirin combination therapy (B).
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Figure 2. Retinal fluorescein angiography reveals characteristic multiple pinpoint leakages of fluorescein from the choroid into the 
subretinal space on the right eye (A) and the left eye (B).
fibrosis, but she refused. She was commenced on pegylated 
interferon-α2b 80 μg (1.5 μg/kg) weekly by subcutaneous 
injection and ribavirin 400 mg orally twice daily. Serum 
HCV RNA level decreased below 25 copies/mL within 12 
weeks after the start of interferon, thus she achieved an early 
viral response.
After 9 months of interferon and ribavirin treatment, the 
patient complained of blurred vision and headache. On 
physical examination, the vitiligo around her forehead and 
scalp was shown (Fig. 1), but there was no sign of meningeal 
irritation. Optic fundal examination showed uveitis and 
retinal edema. Retinal fluorescein angiography (Fig. 2) 
showed leakage of fluorescein dye from the choroid into the 
subretinal space. The serous retinal detachment was seen 
clearly in the right eye from optimal coherence tomography 
(Fig. 3A). Cerebrospinal fluid examination and the magnetic 
resonance imaging (MRI) to identify the encephalomeningitis 
showed no abnormal findings. The level of angiotensin- 
converting enzyme showed normal range, the erythrocyte 
sedimentation rate and the C-reactive protein were also 
normal, and the antinuclear antibody and the rheumatoid 
factor were negative. She was diagnosed as having incomplete 
VKH disease, therefore pegylated interferon-α2b and ribavirin 
were discontinued, and intravenous pulses of methyl-Jae Hee Lim, et al. Vogt-Koyanagi-Harada disease in chronic hepatitis C  63
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Figure 3. Optimal coherence tomography of the right eye shows serous retinal detachments (arrows) with subretinal septa (A). The 
retinal detachment improved at 2 weeks after the steroid therapy (B).
prednisolone at a dose of 1 g for 3 days, followed by daily 
oral administration at a dose of 60 mg prednisolone were 
introduced. After 2 weeks of steroid therapy, her eyesight was 
getting better, and retinal detachment disappeared (Fig. 3B). 
Prednisolone was progressively tapered to 10 mg daily 
during next two months, but relapse occurred. Intravenous 
pulses of methylprednisolone followed by oral prednisolone 
were performed. The uveitis and visual acuity improved. 
While the HCV RNA had not been detected during the 
treatment of pegylated interferon-α2b and ribavirin, serum 
HCV RNA level increased to 3.0×10
7copies/mL after ceasing 
of interferon based therapy. Oral prednisolone was slowly 
tapered to 10 mg daily and no relapse occurred.
DISCUSSION 
Most of ophthalmological complications occurring during 
interferon therapy are benign, transient, and characterized by 
interferon-related retinopathy. Incidence of interferon-related 
retinopathy such as hemorrhage and cotton wool spots vary 
from 6 to 13%.
4 The rate of these complications is reported 
to be higher in patients with diabetes or hypertension, but is 
not related with HCV genotypes, platelet counts or types or 
dose of interferon.
5 More than 90% of the retinal diseases 
during the interferon treatment occur within the first 8 weeks. 
Therefore, the retinal test must be carefully implemented 
from the time before interferon treatment to the 8 weeks 
after initial treatment. Even though it can lead to permanent 
vision loss without proper treatment in the early stage, most 
retinal complications were asymptomatic, not associated 
with impairment of visual acuity, and reversible after 
discontinuation of interferon therapy.
6,7 There are two severe 
forms of intraocular complications which result in severe 
visual impairment. The first form is represented by VKH, 
one of the inflammatory intraocular disorders and the second 
form is retinal vascular disorders including central retinal 
arterial/venous occlusion.
The VKH disease was first described as poliosis, vitiligo, 
anterior uveitis, and tinnitus by Vogt and Koyanagi, and 
described as posterior uveitis with retinal detachment by 
Harada in 1926. The VKH disease is a rare multisystem 
syndrome that attacks melanocytes-containing tissue such as 
eye, skin, hair, inner ear, and cerebral meninges.
3 This can be 
divided into 4 phases; prodromal neurologic phase, acute 
uveitis phase, chronic convalescent phase that is characterized 
by a progressive depigmentation of the skin and the fundus, 
and chronic recurrent phase.
8 This mainly occurs in 30 to 40 
year old women and more frequently in Asian, Latino, 
Native American, or Asian Indian.
8,9
The pathophysiological mechanism of this disease is not 
obviously known, but it is presumed to be an autoimmune 
response of the type 1 helper T-cell (Th1) to antigens related 
with melanocytes.
9,10 This can be supported by the fact that 
when lymphocytes of the patient with VKH are exposed to 
melanocytes, the lymphocytes proliferate significantly.
11 
Cutaneous injury or viral infection may induce sensitization 
of melanocyte and may precipitate the VKH disease. And 
also, thyroid disease or rheumatoid arthritis can be associated 
with VKH disease.
12,13
Interferon enhances lymphocyte cytotoxicity, reveals class 
I antigens of major histocompatibility complex, and diffe-
rentiates antigen-presenting cells. It might also make people 64  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 1. Revised criteria for diagnosis of Vogt-Koyanagi-Harada disease
*
Complete VKH: Criteria 1-5 must be present
Incomplete VKH: Criteria 1-3 and either 4 or 5 must be present
Probable VKH (isolated ocular disease): Criteria 1-3 must be present
1. No history of penetrating ocular trauma or surgery preceding the initial onset of uveitis
2. No clinical or laboratory evidence suggestive of other ocular disease entities
3. Bilateral ocular involvement (a or b must be met, depending on the stage of disease when the patient is examined)
a) Early manifestations of disease
1) Evidence of diffuse choroiditis (with or without anterior uveitis, vitreous inflammatory reaction, or optic disk hyperemia) 
which may manifest as (a) focal areas of subretinal fluid, or (b) bullous serous retinal detachments
b) Late manifestations of disease 
1) History suggestive of prior presence of early findings noted in 3a and either 2) or 3) below, or multiple signs from 3.
2) Ocular depigmentation: either (a) sunset glow fundus or (b) Sugiura’s sign
3) Other ocular signs including (a) nummular chorioretinal depigmented scars, or (b) retinal pigment epithelium clumping 
and/or migration, or (c) recurrent or chronic anterior uveitis
4. Neurological/auditory findings (may resolve by time of evaluation)
a) Meningismus (malaise, fever, headache, nausea, abdominal pain, stiffness of the neck and back, or a combination of these 
factors); note that headache alone is not sufficient to meet the definition of meningismus 
b) Tinnitus
c) Cerebrospinal fluid pleocytosis
5. Integumentary findings (not preceding onset of central nervous system or ocular disease)
a) Alopecia, or
b) Poliosis, or
c) Vitiligo
* Adapted from Read et al.
17
sensitive to autoimmune diseases easily get ill through 
increasing the productions of proinflammatory cytokines, 
and worsen autoimmune diseases such as lupus, rheumatoid 
arthritis, and psoriasis.
14,15 Indeed, there are a few case reports 
about VKH disease occurrence in the treatment combined 
with interferon and ribavirin for chronic hepatitis C.
16 
The occurrence of VKH disease in patient with HCV 
infection before interferon therapy also arouses suspicion 
regarding the role of the HCV in the pathogenesis of the 
disease.
16 Molecular mimicry between viral antigens and 
melanocyte-related antigens could lead to VKH disease. 
However, most reports about its occurrence during interferon 
treatment for chronic hepatitis C suggest that interferon 
therapy rather than HCV infection per se may play a role in 
the development of VKH.
17
In order to achieve successful outcome and to prevent 
complications associated with interferon, selection of patients 
for the treatment is most important. Generally, the ones who 
have persistently normal alanine aminotransferase (ALT) 
levels were not a good candidate for the treatment since 
individuals with persistently normal ALT values have 
significantly less liver fibrosis than whom that have 
abnormal ALT levels.
18 In this case, her liver function tests 
were normal on her first visit to our hospital, but levels of 
transaminase had been shown above than 40 IU/L several 
times in her family doctor’s clinic. Therefore she was not a 
person who had persistently normal ALT levels, and was 
worried about progression of liver disease and wanted to 
treat chronic hepatitis C. Hence, we decided to start 
interferon and ribavirin therapy without confirm of liver 
histology. 
The revised diagnostic criteria of VKH disease (Table 1) 
has been clarified.
16,17 While five items must be satisfied to 
be diagnosed as a complete VKH disease, it is diagnosed as 
an incomplete VKH disease when four items including a 
symptom among neurologic or dermatological conditions 
are satisfied. The present patient had no vitiligo before the 
interferon therapy (Fig. 1A), after 9 months of starting interferon 
therapy, about 5 cm sized patches of de-pigmentation were 
seen around both lateral side of her forehead symmetrically. 
Thus the patient met the criteria for incomplete VKH 
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The treatment of the VKH disease is performed mainly 
using high dose of steroid, and the aggressive treatment in 
the early stage is important to turn around the eye-related 
symptoms.
9 Administration of corticosteroid and stopping 
antiviral agents controlled ocular manifestations in the past 
reports about VKH disease associated with interferon/ribavirin. 
Also in our case, discontinuation of interferon/ribavirin and 
high-dose systemic steroid therapy could improve ocular 
changes and visual outcomes. To treat the recurrent or steroid- 
resistant VKH disease, cyclosporine, antimetabolites, and 
alkylating agent have been used.
19 
Several treatment modalities can improve vitiligo. Commonly 
used repigmentation therapies including ultraviolet light 
and/or topical applications of corticosteroids or calcineurin 
inhibitors are sometimes effective.
20 Depigmentation of the 
unaffected skin is another option in cases of extensive 
vitiligo. However, there is no cure for vitiligo. In this case, 
her skin lesions were not improved despite systemic and 
topical corticosteroid agents.
In summary, VKH disease, which can be induced by 
pegylated interferon-α2b and ribavirin combination therapy 
may lead to irreversible visual loss. Thereby, awareness of 
screening for ocular manifestations and early treatment are 
necessary. 
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